We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Two Alzheimer's risk genes linked to brain atrophy, promise future blood markers
News

Two Alzheimer's risk genes linked to brain atrophy, promise future blood markers

Two Alzheimer's risk genes linked to brain atrophy, promise future blood markers
News

Two Alzheimer's risk genes linked to brain atrophy, promise future blood markers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Two Alzheimer's risk genes linked to brain atrophy, promise future blood markers "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Two genetic variants previously linked to Alzheimer's disease have been more specifically tied to brain atrophy that is characteristic of the disease.


A newly reported study, led by Liana Apostolova, MD, Barbara and Peer Baekgaard Professor of Alzheimer's Disease Research at the Indiana University School of Medicine, also found that the proteins produced by the genes and circulating in the blood were associated with the brain atrophy and could be used in Alzheimer's-related tests in the future.


The study is believed to be the first to directly link common variants of the genes—ABCA7 and MA4A6A—to atrophy in cortical and hippocampal regions of the brain, which are associated with memory and other key functions. It's also believed to be the first to link the atrophy to protein levels in the blood produced by the genes.


"We also found that the levels of the protein products of these genes, circulating in the peripheral blood, were associated with the cortical and hippocampal atrophy. This finding suggests that those results of gene expression could become useful biomarker blood tests for Alzheimer's disease," Apostolova said.


The study is published in the journal Neurobiology of Aging.


There is no cure for Alzheimer's and currently available treatments can slow, but cannot stop, the deterioration associated with the disease.


Although scientists have been linking a growing number of gene variants to the risk of developing Alzheimer's disease, most of the associations have not identified the specific mechanisms that would increase the risk of developing the disease.


For the new study, the researchers identified the top nine genetic variants that have been associated with Alzheimer's disease risk, not including the APOe4 gene that has long been linked to increased risk for several characteristics of Alzheimer's disease.


Using magnetic resonance imaging tools to measure brain size and genetic analysis, the researchers looked for associations between the genetic variants and atrophy in the cortical and hippocampal regions of the brain, which are established physical biomarkers of Alzheimer's disease. The studies were conducted in 50 participants with no cognitive difficulties and 90 who had been diagnosed with mild cognitive impairment, a condition that is associated with increased risk of developing Alzheimer's disease. All of the participants were 50 years or older.


Just two of the genetic variants—known as ABCA7 and MA4A6A—appeared to be associated with the changes in brain structure.


Note: Material may have been edited for length and content. For further information, please contact the cited source.

Indiana University Bloomington   press release


Publication

Ramirez LM et al. Common Variants in ABCA7 and MSA46A are Associated with Cortical and Hippocampal Atrophy.   Neurobiology of Aging, Published Online November 5 2015. doi: 10.1016/j.neurobiolaging.2015.10.037


Advertisement